[Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
OBJECTIVE
CAF regimen [Cytoxan+ Adriamycin+5-fluorouracil (5-FU)] and TP regimen (paclitaxel+cisplatin) were effective to advanced breast cancer (ABC). But TP regimen was expensive and the administration was complicated. So the authors evaluated the clinical results of CAF and TP regimens.


METHODS
A total of 117 ABC patients proved pathologically were divided into CAF and TP groups. Patients in both groups were well matched with baseline disease characteristics (P >0.05). CAF group (66 cases):received Cytoxan 600 mg/m(2), i.v. drip d(1), Adriamycin 60 mg/m(2) i.v. drip d(1) and 5-FU 600 mg/m(2), i.v. drip d(1,8); TP group (51 cases): received paclitaxel 135 mg/m(2) by i.v. drip for 3 hours and cisplatin 60 mg/m(2), i.v. drip d(2-3) The treatments were repeated every 3 weeks. All patients received two cycles of the treatment at least.


RESULTS
In CAF group, the response rates (RR) of the initial treatment cases, the retreatment cases, and the whole cases were 54.8% (17/31), 31.4% (11/35), and 42.4% (28/66), respectively. The median time to progression (TTP) was 7.8 months (95%CI:5.3-10.8 months) and the median survival was 17.8 months (95%CI:13.3-22.5%). Whereas in TP group, the RR of the initial treatment cases, the retreatment cases, and the whole cases were 62.5%(15/24), 59.3%(16/27), and 60.8%(31/51), respectively. The median TTP and the median survival were 8.6 months (95%CI:6.5-12 months) and 19 months (95%CI:15-25.5 months), respectively. There were significant differences between two groups in the RR of retreatment cases and the whole cases (P< 0.05, Chi-square test). However, there was no significant difference in the RR of the initial treatment cases, the median TTP and median survival (for RR, P >0.05, Chi-square test; for median TTP and median survival, P >0.05, Log-rank test). Diarrhea was more serious in CAF group than in TP group; however, myodynia, peripheral neuropathy,and skin exanthem were more serious in TP group than in CAF group(P< 0.05,Wilcoxon rank sum test). There was no significant difference in the other side effects between the two groups. All side effects were tolerable.


CONCLUSIONS
CAF regimen was still a firstly selected regimen for the patients with ABC.
Lin
Xian-Gan
XG
Department of Oncology, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
Xie
De-Rong
DR
Yao
He-Rui
HR
Li
Zhi-Hua
ZH
Jiang
Zhi-Min
ZM
Liu
Tian-Hao
TH
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D043823:Taxoids; D016896:Treatment Outcome
D043823:Taxoids; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil